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ABSTRACT
Background. Systemic inflammatory response (SIR) is an
adverse prognostic marker in colorectal cancer (CRC)
patients. The ScotScan Colorectal Cancer Group was
established to examine how markers of the SIR differ
between populations and may be utilised to guide
prognosis.
Patients and Methods. Patients undergoing resection of
stage I–III CRC from two prospective datasets in Scotland
and Norway were included. The relationship between the
modified Glasgow Prognostic Score (mGPS; combination
of C-reactive protein and albumin) and overall survival
(OS) was examined. The relationship between OS, adju-
vant chemotherapy regime and mGPS was examined in
patients with stage III colon cancer.
Results. A total of 2295 patients were included. Patients
from Scotland were more inflamed despite controlling for
associated characteristics using multivariate logistic
regression or propensity score matching (OR 2.82, 95% CI
1.98–4.01, p\ 0.001). mGPS had similar independent
prognostic value in both cohorts (Scotland: HR 1.27, 95%
CI 1.12–1.45; Norway: HR 1.23, 95% CI 1.01–1.49) and
stratified survival independent of TNM group in the whole
cohort. In patients with stage III colon cancer receiving
adjuvant therapy, there appeared to be a survival benefit in
systemically inflamed patients receiving oxaliplatin but not
single-agent 5-fluorouracil or capecitabine.
Conclusions. The SIR differs between populations from
different countries; however prognostic value remains
similar. The present study strongly supports the routine
reporting of the mGPS in patients with CRC.
Systemic inflammation is an important determinant of
disease progression and outcome in patients with cancer.1
The body of evidence supporting the routine assessment of
indices of the systemic inflammatory response (SIR) as
prognostic markers is such that recent consensus statements
have proposed their mandatory inclusion in future oncol-
ogy trials of patients with advanced colorectal and
pancreatic cancer.2,3
Similarly, markers of the SIR may also inform prognosis
of patients undergoing potentially curative treatment. In
this regard, two recent meta-analyses have confirmed the
independent prognostic value of the modified Glasgow
Prognostic Score (mGPS), a cumulative score based on
circulating serum C-reactive protein (CRP) and albumin
concentrations, in patients with primary operable colorectal
cancer.4,5 A model by which the combination of TNM
stage and mGPS could be utilised to determine prognosis
following surgical resection in patients with stage I–III
disease has previously been proposed.6 Using such a
scheme provides further risk stratification than either
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measure alone; for example, whereas 5-year cancer-speci-
fic survival of patients with stage III colon cancer overall
was 63%, the addition of the mGPS further stratified sur-
vival from 75 to 37%.
However, although of use in determining prognosis,
whether the systemic inflammatory response may also aid
in the selection of patients for adjuvant therapy remains to
be determined. Both observational studies and clinical tri-
als have confirmed that the mGPS and related scores retain
prognostic significance in patients receiving chemotherapy
and radiotherapy.6–8 Whether this represents a need to
select the appropriate chemotherapy regime and duration
on the basis of the SIR or simply reflects futility of con-
ventional cytotoxic chemotherapy in the presence of
systemic inflammation remains unclear.
The ScotScan Collaborative was established by two
multidisciplinary groups from Glasgow, United Kingdom,
and Southern Hospital Trust, Norway, with a mutual
interest in the role of host inflammatory responses in
determining oncological outcomes in patients with col-
orectal cancer. It was perceived that the combined
resources of these two groups could be utilised to address a
number of unanswered questions and further refine the
clinical application of inflammatory-based measures to
determine prognosis and treatment strategies of patients
with colorectal cancer. In the present study, the ScotScan
Collaborative dataset is described and the relationships
between mGPS and survival are reported. Furthermore, this
combined dataset is used to further examine the relation-
ship between mGPS, adjuvant therapy and survival of
patients with stage III colon cancer.
PATIENTS AND METHODS
Scotish and Norwegian Cohort
Patients were identified from a prospectively maintained
database of colorectal cancer resections performed at
Glasgow Royal Infirmary since January 1997 and at
Southern Hospital Trust in Norway since January 2000. For
the present work, patients who underwent resection of
TNM stage I–III colorectal adenocarcinoma between Jan-
uary 1997 and June 2015 in Scotland and between January
2000 and May 2017 in Norway with curative intent (based
on pre-operative cross-sectional imaging and intra-opera-
tive findings) were included. Both elective and emergency
cases were included. Patients who underwent palliative or
localised resection and those who did not have pre-opera-
tive measurement of CRP were excluded.
Serum albumin and CRP were measured at pre-opera-
tive assessment within 30 days of surgery for elective
patients and on day of admission for patients undergoing
emergency surgery. The mGPS was calculated as previ-
ously described; 9 patients with CRP B 10 mg/L were
allocated a score of 0; patients with CRP[ 10 mg/L alone
were allocated a score of 1; and patients with CRP[ 10
mg/L and albumin\ 35 g/L a score of 2. Pathological
staging of tumours was performed using TNM fifth edition
for patients from Scotland, consistent with contemporary
reporting guidelines during the time period studied.10 In
Norway, the fifth TNM edition was used until January
2009, seventh edition until August 2017 and eighth edition
afterwards. Tumours were classified as right (caecum to
distal transverse), left (splenic flexure to rectosigmoid) and
rectal (distal to rectosigmoid).
All patients were discussed at weekly colorectal cancer
multidisciplinary meetings prior to and following surgery.
Those with both node-positive disease and node-negative
disease with high-risk characteristics (i.e. T4, perforation,
venous invasion) were considered for systemic adjuvant
chemotherapy. Patients were routinely followed up for
5 years, according to local institutional guidelines. Date
and cause of death were confirmed using hospital elec-
tronic case records; follow-up and confirmation of vital
status were censored on 30 June 2017 for patients from
Scotland. Date of last recorded follow-up or last review of
electronic case records (31 December 2017) acted as the
censor date for patients from Norway. Overall survival was
measured from date of surgery for Scotland and first con-
firmed biopsy (including surgery) for Norway, until date of
death from any cause. Cancer-specific survival was mea-
sured until date of death from radiologically or
histologically confirmed recurrent colorectal cancer. Local
institutional ethics approval was obtained from both
hospitals.
Statistics
Categorical data were examined using v2 analysis for
linear trend, and the relationship between clinicopatho-
logical characteristics and the mGPS was examined using
binary logistic regression to calculate odds ratios (OR) and
95% confidence intervals (CI). To test for independence, a
multivariate backwards conditional model was constructed
using variables with p\ 0.05 on univariate analysis. To
further account for differences in clinical and pathological
characteristics associated with the two different cohorts,
propensity score matching was also performed using the
following variables: age, American Society of Anesthesi-
ologists (ASA) grade, presentation, neoadjuvant therapy,
tumour location, T stage, N stage and differentiation.
The relationship between clinicopathological character-
istics and overall survival and cancer-specific survival was
examined using Cox proportional hazards regression to
calculate hazard ratios (HR) and 95% CI. Multivariate
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survival analysis was performed using a backwards con-
ditional method, including variables with p\ 0.05 on
univariate analysis. To account for differences in treatment
over the time period studied, year of surgery was divided
into quartiles and entered as a variable into all multivariate
models. Three-year overall survival was reported as per-
centage surviving [standard error (SE)] and displayed using
Kaplan–Meier curves, with log-rank survival analysis to
compare survival between groups. A p value\ 0.05 was
considered statistically significant. All analyses were per-
formed using SPSS version 25 for Mac (IBM SPSS,
Armonk NY, USA).
RESULTS
The ScotScan Cohort
The clinicopathological characteristics of 2295 patients
who underwent resection of stage I–III colorectal cancer in
Scotland (n = 1234) and in Norway (n = 1061) are dis-
played in Table 1. Patients from Norway were more likely
to be older, female and have more comorbidity
(p\ 0.001). Patients from Scotland were more likely to
have had surgery for rectal cancer and more advanced
TNM stage. Emergency presentation and neoadjuvant
chemoradiotherapy use were comparable between groups,
however patients from Scotland were more likely overall to
receive adjuvant chemotherapy. When categorised by
stage, patients from Scotland were more likely to receive
adjuvant therapy for stage II disease (17% versus 2%,
p\ 0.001), whereas those from Norway were more likely
to receive adjuvant therapy for stage III disease (54%
versus 47%, p\ 0.001). Patients from Scotland were more
likely to be systemically inflamed prior to surgery as
measured by both CRP[ 10 mg/L and mGPS (both
p\ 0.001).
Relationship Between Clinicopathological
Characteristics and mGPS
Differences in SIR between the two cohorts were
examined using both the whole cohort and a propensity
score matched cohort. On univariate binary logistic
regression analysis (Table 2), advancing age and ASA
grade, emergency presentation, advancing T and N stage
and poor tumour differentiation were all associated with an
elevated mGPS, whereas male sex, Norwegian cohort, year
of surgery quartile, neoadjuvant therapy and rectal primary
were associated with lower risk of an elevated mGPS. On
multivariate analysis, male sex (OR 0.74, p = 0.007),
Norwegian cohort (OR 0.65, p\ 0.001), high ASA grade
(OR 1.32, p\ 0.001), year of surgery (OR 0.75,
p\ 0.001), emergency presentation (OR 4.34, p\ 0.001),
distal primary location (OR 0.72, p\ 0.001), advancing T
stage (OR 2.13, p\ 0.001) and poor differentiation (OR
2.04, p\ 0.001) were all independently associated with
mGPS.
Propensity score matching was performed to match the
two cohorts (Supplementary Fig. 1); despite close match-
ing on the basis of stage and clinical characteristics
(n = 736, Supplementary Table 1), patients from Scotland
remained more likely to be systemically inflamed prior to
surgery (mGPS C 1, OR 2.82, 95% CI 1.98–4.01,
p\ 0.001). When patients were stratified by year of sur-
gery, those from Scotland again remained more likely to be
systemically inflamed (data not shown).
To account for differences in treatment modalities in
patients with rectal cancer, further analysis was performed
in the unmatched cohort, including only patients with colon
cancer undergoing surgery without prior neoadjuvant
treatment (n = 1618). Patient demographics reflected those
of the original cohort (Supplementary Table 2). Patients
from Scotland remained more likely to be systemically
inflamed; on multivariate analysis, sex, country cohort,
ASA grade, year of surgery, emergency presentation, T
stage and differentiation all remained independently asso-
ciated with mGPS (Table 2).
Survival
Thirty-day mortality was 2% (54 patients); these
patients were excluded from survival analysis (n = 2241).
Median follow-up of survivors from Scotland was
70 months (interquartile range 45–120), with 300 cancer-
associated and 264 non-cancer deaths; median follow-up of
survivors from Norway was 29 months (8–51), with 94 and
137 cancer-associated and non-cancer deaths, respectively.
On both univariate and multivariate analysis, the mGPS
had comparable prognostic value for overall survival in
both patient cohorts (Supplementary Table 3; Scotland:
multivariate HR 1.27, 95% CI 1.12–1.45, p\ 0.001;
Norway: multivariate HR 1.23, 95% CI 1.01–1.49,
p = 0.043); therefore, further survival analysis was per-
formed on the combined cohort.
On multivariate survival analysis (Table 3), mGPS
remained associated with overall survival (HR 1.28, 95%
CI 1.15–1.43, p\ 0.001) independent of age, ASA grade,
year of surgery quartile, adjuvant therapy, T stage and N
stage, and with cancer-specfic survival (HR 1.36, 95% CI
1.15–1.61, p\ 0.001) independent of ASA grade, year of
surgery, T stage and N stage. Furthermore, the mGPS
remained independently associated with survival when
analysis was repeated in patients with colon cancer only
(n = 1579, overall survival: HR 1.21, 95% CI 1.06–1.39,
p = 0.005; cancer-specific survival: HR 1.26, 95% CI
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TABLE 1 Comparison of clinicopathological characteristics of patients from Scotland and Norway undergoing potentially curative resection of
stage I–III colorectal cancer
Clinicopathological characteristics Scotland Norway p
(N = 1234) (%) (N = 1061) (%)
Age (years) \ 0.001
\ 65 420 (34) 248 (23)
65–74 431 (35) 327 (31)
[ 75 383 (31) 486 (46)
Sex \ 0.001
Female 547 (44) 562 (53)
Male 687 (56) 499 (47)
ASA grade (1883) \ 0.001
I 167 (19) 43 (4)
II 366 (42) 411 (41)
III 310 (35) 505 (50)
IV 39 (4) 42 (4)
Presentation (2294) 0.497
Elective 1118 (91) 969 (91)
Emergency 116 (9) 91 (9)
Year of surgery \ 0.001
1997–2005 454 (37) 58 (6)
2006–2010 297 (24) 223 (21)
2011–2013 319 (26) 254 (24)
2014–2017 164 (13) 526 (49)
Neoadjuvant therapy (2287) 0.634
No 1102 (90) 960 (90)
Yes 124 (10) 101 (10)
Adjuvant chemotherapy (2248) \ 0.001
No 279 (74) 904 (85)
Yes 308 (26) 157 (15)
Tumour subsite \ 0.001
Right 449 (37) 464 (44)
Left 376 (31) 339 (32)
Rectum 403 (33) 258 (24)
T stage \ 0.001
0 16 (1) 13 (1)
1 93 (7) 101 (10)
2 142 (12) 201 (19)
3 677 (55) 691 (65)
4 306 (25) 55 (5)
N stage 0.001
0 767 (62) 722 (68)
1 330 (27) 255 (24)
2 137 (11) 84 (8)
TNM stage \ 0.001
PCR 16 (1) 12 (1)
I 196 (16) 259 (24)
II 555 (45) 451 (43)
III 467 (38) 339 (32)
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1.03–1.55, p = 0.025) and when emergency patients were
excluded (n = 1393, overall survival: HR 1.26, 95% CI
1.10–1.45, p = 0.001; cancer-specific survival: HR 1.29,
95% CI 1.03–1.621, p = 0.025). To account for differences
in ascertainment of survival data between cohorts, only
overall survival was examined in further analyses.
The relationship between TNM stage, mGPS and 3-year
overall survival of patients undergoing resection of colon
cancer was further examined (Fig. 1). Overall 3-year sur-
vival of the combined cohort was 73%; TNM stratified
survival from 82% (TNM I) to 58% (TNM III), whereas
mGPS stratified survival from 74 to 46% (both p\ 0.001).
When combined, mGPS was able to stratify survival within
TNM stage; for example 3-year overall survival of patients
with stage I colon cancer was 85% (mGPS 0, n = 234),
67% (mGPS 1, n = 25) and 27% (mGPS 2, n = 7). Simi-
larly, 3-year survival of patients with stage III disease was
67% (mGPS 0, n = 340), 53% (mGPS 1, n = 143) and 33%
(mGPS 2, n = 85).
Subgroup analysis of patients undergoing elective
resection of rectal cancer (n = 425) without neoadjuvant
chemoradiotherapy was performed. The mGPS was asso-
ciated with increasing T stage (p\ 0.001) but no other
clinical or pathological characteristics (data not shown).
Small numbers within individual TNM/mGPS groups
precluded meaningful analysis by stage, however the
mGPS stratified 3-year overall survival from 86 to 76%
(p = 0.009), and cancer-specific survival from 90 to 83%
(p = 0.03).
Subgroup analysis of patients undergoing emergency
resection (n = 207) was performed. Over 95% of patients
underwent surgery for a T3/4 tumour, and 49% had node
positive disease; 71% of patients were systemically
inflamed at time of surgery; neither overall (p = 0.546) nor
cancer-specific survival (p = 0.219) differed significantly
between groups. Patient and tumour characteristics and use
of adjuvant therapy were not associated with pre-operative
systemic inflammatory response in those patients under-
going emergency resection (data not shown).
Systemic Inflammation, Adjuvant Therapy and Overall
Survival
Survival was examined in 482 patients with stage III
colon cancer in whom adjuvant chemotherapy status was
known (Fig. 2). Patients with stage III colon cancer in
whom chemotherapy data were missing were more likely
to be younger and male but did not differ with respect to T
stage or mGPS (data not shown). For the purposes of fur-
ther analysis, systemic inflammatory status was categorised
as mGPS = 0 or mGPS C 1, with 3-year overall survival of
76% and 65%, respectively (p = 0.01). Chemotherapy
status was categorised as no chemotherapy (n = 262),
5-fluorouracil-based (5-FU) single-agent therapy (either
infusional 5-FU or oral capecitabine, n = 72) or oxali-
platin-based combination therapy (with either oral or
infusional 5-FU, n = 148), with 3-year survival of 60%,
76% and 90%, respectively (p\ 0.001).
In patients with mGPS = 0, 5-FU and oxaliplatin-based
chemotherapy were both associated with improved survival
compared with patients not receiving adjuvant therapy
(p\ 0.001). In patients with mGPS C 1 however, only
oxaliplatin-based chemotherapy was associated with
improved survival compared with no treatment
Table 1 (continued)
Clinicopathological characteristics Scotland Norway p
(N = 1234) (%) (N = 1061) (%)
Differentiation (2204) \ 0.001
Well/mod 1103 (91) 839 (85)
Poor 115 (9) 147 (15)
C-reactive protein 0.001
B 10 mg/L 807 (65) 761 (72)
[ 10 mg/L 427 (35) 300 (28)
Albumin \ 0.001
C 35 g/L 900 (73) 937 (88)
\ 35 g/L 334 (27) 124 (12)
mGPS \ 0.001
0 807 (65) 761 (72)
1 231 (19) 201 (19)
2 196 (16) 99 (9)
(n) given when incomplete data available. p value given for v2 method for linear trend for categorical variables
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(p\ 0.001), with 3-year survival comparable to non-in-
flamed patients receiving either 5-FU or oxaliplatin. In
contrast, patients with mGPS C 1 receiving 5-FU only had
no better 3-year overall survival than those without adju-
vant chemotherapy.
The clinicopathological characteristics of patients
receiving adjuvant chemotherapy were examined (Supple-
mentary Table 4). Of patients receiving 5-FU alone, those
with an elevated CRP were more likely to have been
operated on during an earlier time period, have a higher T
stage (both p\ 0.05) and show a trend towards emergency
presentation and poor differentiation. Of those patients
receiving combined oxaliplatin therapy, an elevated CRP
was associated with emergency presentation, T stage and
differentiation (all p B 0.001) and showed a trend towards
more proximal tumour location. When comparison was
made between patients with an elevated CRP receiving
different chemotherapy regimens, patients receiving
oxaliplatin combination therapy were more likely to be
younger (p\ 0.001) and show a trend towards lower ASA
grade (p = 0.091).
DISCUSSION
Utilising a dataset of over 2000 patients from two
Northern European countries, the present study is, to the
best of the authors’ knowledge, the largest prospective
dataset in operable stage I–III CRC to date examining the
systemic inflammatory response and outcome, and further
confirms the strong prognostic value of the mGPS inde-
pendent of disease stage.
The proportion of patients exhibiting elevated systemic
inflammatory responses differed between the two popula-
tions, with patients from Scotland more likely to be
systemically inflamed. These differences persisted even
after controlling for clinical and pathological factors
known to be associated with the systemic inflammatory
response. Previous studies comparing differing populations
with colorectal cancer have suggested that ethnicity is
associated with systemic inflammatory responses prior to
surgery.11 However, the two populations presently studied
are Northern European, with both hospitals serving regions
with predominantly Caucasian populations. In addition,
TABLE 2 Relationship between clinicopathological characteristics and presence of elevated systemic inflammatory responses (mGPS C 1) in
patients undergoing potentially curative resection of stage I–III colorectal cancer in Norway and Scotland
Univariate OR (95% CI) p Multivariate OR (95% CI) p
Full cohort (N = 2295)
Age (\ 65/65–74/[ 74) 1.23 (1.10–1.37) \ 0.001 – 0.317
Sex (female/male) 0.76 (0.63–0.90) 0.002 0.75 (0.60–0.94) 0.012
Centre (Scotland/Norway) 0.75 (0.62–0.89) 0.001 – 0.321
ASA grade (I/II/III/IV) 1.40 (1.23–1.61) \ 0.001 1.25 (1.07–1.45) 0.004
Year of surgery quartile 0.73 (0.67–0.79) \ 0.001 0.75 (0.68–0.83) \ 0.001
Presentation (elective/emergency) 6.20 (4.53–8.49) \ 0.001 4.58 (3.09–6.77) \ 0.001
Neoadjuvant therapy (no/yes) 0.34 (0.23–0.50) \ 0.001 – 0.213
Tumour site (right/left/rectum) 0.59 (0.53–0.66) \ 0.001 0.71 (0.61–0.82) \ 0.001
T stage (0/1/2/3/4) 2.58 (2.24–2.97) \ 0.001 2.16 (1.80–2.60) \ 0.001
N stage (0/1/2) 1.26 (1.11–1.44) \ 0.001 – 0.096
Differentiation (mod-well/poor) 2.76 (2.13–3.59) \ 0.001 2.11 (1.53–2.90) \ 0.001
Colon cancer without neoadjuvant therapy (N = 1618)
Age (\ 65/65–74/[ 74) 1.17 (1.03–1.32) 0.016 – 0.239
Sex (female/male) 0.79 (0.64–0.96) 0.020 0.73 (0.57–0.93) 0.013
Centre (Scotland/Norway) 0.79 (0.64–0.96) 0.019 – 0.835
ASA grade (I/II/III/IV) 1.30 (1.11–1.51) 0.001 1.21 (1.02–1.44) 0.025
Year of surgery quartile 0.74 (0.67–0.80) \ 0.001 0.78 (0.70–0.87) \ 0.001
Presentation (elective/emergency) 4.91 (3.55–6.79) \ 0.001 4.13 (2.78–6.14) \ 0.001
Tumour site (right colon/left colon) 0.72 (0.59–0.89) 0.002 – 0.090
T stage (0/1/2/3/4) 2.55 (2.16–3.02) \ 0.001 2.01 (1.64–2.47) \ 0.001
N stage (0/1/2) 1.27 (1.10–1.48) 0.001 – 0.231
Differentiation (mod-well/poor) 2.84 (2.12–3.81) \ 0.001 2.25 (1.59–3.19) \ 0.001
HR hazard ratio, CI confidence interval, ASA American Society of Anesthesiologists
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TABLE 3 Relationship between clinicopathological characteristics and overall survival of patients undergoing potentially curative resection of
stage I–III colorectal cancer
Overall survival Cancer-specific survival
Univariate HR
(95% CI)
p Multivariate
HR (95% CI)
p Univariate HR
(95% CI)
p Multivariate
HR (95% CI)
p
Full cohort (N = 2241)
Age (\ 65/65–74/[ 74) 1.82 (1.65–2.00) \ 0.001 1.48
(1.31–1.67)
\ 0.001 1.22 (1.08–1.39) 0.002 – 0.610
Sex (female/male) 1.12 (0.97–1.29) 0.132 – – 1.21 (0.99–1.50) 0.067 – 0.075
ASA grade (I/II/III/IV) 2.11 (1.87–2.38) \ 0.001 1.72
(1.50–1.96)
\ 0.001 1.65 (1.39–1.96) \ 0.001 1.45
(1.21–1.74)
\ 0.001
Presentation (elective/
emergency)
1.64 (1.31–2.04) \ 0.001 – 0.179 2.44 (1.85–3.22) \ 0.001 – 0.081
Year of surgery quartile 0.78 (0.72–0.85) \ 0.001 0.88
(0.80–0.98)
0.015 0.69 (0.61–0.77) \ 0.001 0.82 (.71–0.94) 0.004
Neoadjuvant therapy (no/
yes)
0.68 (0.51–0.90) 0.007 – 0.724 1.03 (0.74–1.44) 0.853 – –
Adjuvant chemotherapy
(No/yes)
0.73 (0.60–0.88) 0.001 0.71
(0.55–0.91)
0.008 1.22 (0.97-–1.55) 0.093 – 0.054
Tumour site (right/left/
rectum)
0.88 (0.81–0.96) 0.004 – 0.281 1.03 (0.91–1.17) 0.642 – –
T stage (0/1/2/3/4) 1.51 (1.37–1.66) \ 0.001 1.31
(1.15–1.49)
\ 0.001 2.35 (2.00–2.75) \ 0.001 1.92
(1.55–2.38)
\ 0.001
N stage (0/1/2) 1.44 (1.31–1.59) \ 0.001 1.50
(1.32–1.71)
\ 0.001 2.00 (1.75–2.28) \ 0.001 1.77
(1.49–2.11)
\ 0001
Differentiation (mod-
well/poor)
1.37 (1.11–1.70) 0.003 – 0.634 1.46 (1.08–1.97) 0.013 – 0.922
Modified Glasgow
Prognostic Score (0/1/
2)
1.54 (1.41–1.69) \ 0.001 1.28
(1.15–1.43)
\ 0.001 1.67 (1.47–1.89) \ 0.001 1.36
(1.15–1.61)
\ 0.001
Colon cancer without neoadjuvant (N = 1579)
Age (\ 65/65–74/[ 74) 1.94 (1.73–2.17) \ 0.001 1.65
(1.42–1.92)
\ 0.001 1.29 (1.10–1.51) 0.002 – 0.066
Sex (female/male) 1.00 (0.84–1.18) 0.975 – – 1.12 (0.87–1.44) 0.388 – –
ASA grade (I/II/III/IV) 2.28 (1.97–2.64) \ 0.001 1.78
(1.51–2.09)
\ 0.001 1.79 (1.45–2.23) \ 0.001 1.51
(1.21–1.89)
\ 0.001
Presentation (elective/
emergency)
1.66 (1.32–2.09) \ 0.001 1.35
(1.01–1.81)
0.042 2.74 (2.04–3.67) \ 0.001 1.65
(1.13–2.39)
0.009
Year of surgery quartile 0.80 (0.72–0.88) \ 0.001 0.89
(0.79–1.00)
0.051 0.68 (0.59–0.78) \ 0.001 0.81
(0.69–0.95)
0.010
Adjuvant therapy (no/
yes)
0.62 (0.49–0.77) \ 0.001 0.69
(0.51–0.94)
0.017 1.15 (0.866–1.53) 0.334 – –
Tumour site (right colon/
left colon)
0.84 (0.71–0.99) 0.043 – 0.540 0.95 (0.74–1.22) 0.686 – –
T stage (0/1/2/3/4) 1.50 (1.33–1.69) \ 0.001 1.28
(1.09–1.50)
0.003 2.80 (2.27–3.46) \ 0.001 2.31
(1.75–3.04)
\ 0.001
N stage (0/1/2) 1.39 (1.23–1.56) \ 0.001 1.45
(1.25–1.69)
\ 0.001 1.99 (1.70–2.34) \ 0.001 1.65
(1.36–2.01)
\ 0.001
Differentiation (mod-
well/poor)
1.20 (0.94–1.53) 0.142 – – 1.14 (0.79–1.64) 0.497 – –
Modified Glasgow
Prognostic Score (0/1/
2)
1.55 (1.39–1.72) \ 0.001 1.21
(1.06–1.39)
0.005 1.68 (1.45–1.96) \ 0.001 1.26
(1.03–1.55)
0.025
HR hazard ratio, CI confidence interval, ASA American Society of Anesthesiologists
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both ancestry studies and disease susceptibility studies
have suggested genetic homogeneity between Scottish and
Scandinavian populations.12–15 Therefore, this would be
unlikely to account significantly for the differences
observed.
Differences in systemic inflammatory responses may
reflect differences in clinical characteristics and tumour
pathology; for instance increasing age and co-morbidity
both more common in the Norwegian cohort, have
previously been associated with the systemic inflammatory
response in cancer.14,15 Similarly, pathological character-
istics, such as advanced T stage, are associated with the
mGPS and other inflammatory indices.15,16 Despite these
unfavourable characteristics for the Norwegian cohort,
patients from Scotland still exhibited more inflammation
than the Norwegian patients, even after controlling for such
variables using both multivariate adjustment and propen-
sity score matching.
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Similarly, the proportion of systemically inflamed
patients decreased in association with year of surgery in
both cohorts. The reason for this is not clear, however may
represent a change in the characteristics of patients
undergoing surgery for colorectal cancer; For instance
screening was introduced in Scotland 2007–2009, with
patients with screen-detected cancer less likely to have
advanced disease stage at presentation.17 Similarly, opti-
misation of other medical comorbidities in more recently
diagnosed patients may also impact upon the presence of a
systemic inflammatory response. Given that 61% of
patients from Glasgow Royal Infirmary (GRI) underwent
surgery prior to 2011 compared with 27% of patients from
Norway, this may in part explain differences in the pro-
portion of systemically inflamed patients in each of the two
cohorts studied. However, country of origin remained an
independent determinant of the systemic inflammatory
response even after controlling for year of surgery.
The differences in mGPS between the two populations
may therefore reflect clinical and tumour characteristics
presently unaccounted for; for example obesity and life-
style factors are important determinants of elevated
systemic inflammatory responses and were not mea-
sured.18–20 In addition, ASA grade is relatively subjective
and may not fully account for patient co-morbidity,21
particularly when compared across different populations
and healthcare systems. Furthermore, although speculative,
it has recently been suggested that a proportion of patients
with mismatch repair (MMR)-deficient colorectal cancer
may exhibit elevated systemic inflammatory responses;
22,23 however given that only a small proportion of tumours
arise through MMR deficiency, this may only account for
some of the observed differences. It is clear that further
characterisation of both tumour and host immune responses
is required to fully determine the nature of any differences
in systemic inflammatory responses between different
populations.
Despite these observed differences, the mGPS showed
comparable prognostic value in both cohorts. This would
further ratify the mGPS as an inexpensive, readily mea-
sured and internationally applicable prognostic marker in
patients undergoing surgery for colorectal cancer. Indeed,
given the population-based differences in the prevalence of
an elevated mGPS, as described in both this study and
previous work,11 it is clear that such measures should be
routinely adopted if outcomes are to be compared globally,
particularly in the context of future clinical trials.
Emergency presentation is recognised as a predictor of
poor survival of patients undergoing colorectal cancer
resection.24 Consistent with prior work,6,25 emergency
presentation was a determinant of the pre-operative sys-
temic inflammatory response. Of interest, although
approximately one-third of patients undergoing emergency
surgery were not inflamed, this was not reflected by
a
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improved survival of this subgroup. This may reflect the
heterogeneous nature of emergency patients, whereby
some patients may be acutely inflamed due to an acute
event such as perforation or obstruction, thereby necessi-
tating emergency presentation and resection. Further work,
detailing the nature of the systemic inflammatory response
in this population is merited.
Although limited by a small number of patients in each
subgroup, it was of interest that the association between
mGPS and survival in patients receiving adjuvant therapy for
stage III colon cancer appeared to differ with chemotherapy
regime. Whereas an elevated mGPS was associated with
poorer survival of patients receiving single-agent 5-FU-
based chemotherapy, this was not apparent for those
receiving combination therapy with oxaliplatin. The reason
for this may simply reflect bias in the selection of patients for
different chemotherapy regimens, with older more co-mor-
bid patients more likely to receive single-agent therapy in
this cohort. However, it has previously been surmised that
systemically inflamed patients may be less likely to complete
adjuvant chemotherapy due to increased toxicity.9 Therefore
future studies of the relationship between systemic inflam-
mation, adjuvant therapy use and outcome are warranted.
The selection of patients with stage II disease who may
benefit from adjuvant chemotherapy remains unclear, with
current decision-making determined by the presence of high-
risk pathologic criteria.26 Whether the mGPS may aid in
identifying patients likely to benefit would be of considerable
interest. In the present study, only 68 patients with stage II colon
cancer received adjuvant therapy. Given the wide heterogeneity
of tumour pathologic characteristics within this population,
meaningful statistical analysis is precluded. Future studies of
adjuvant therapy in stage II disease, incorporating measures of
the systemic inflammatory response alongside more established
markers of high-risk disease are warranted.
The present study is limited by its use of overall survival
as the primary endpoint for 3-year survival analysis. How-
ever, it has previously been shown that elevated preoperative
CRP is associated with poorer cancer-specific prognosis in
patients with colorectal cancer from both centres.6,15 Here,
the endpoint of overall survival was chosen to account for
potential institutional differences in follow-up protocols and
attainment of mortality data. Furthermore, overall survival is
a pragmatic measure of relevance to patients, and increas-
ingly recognised as a valuable metric for reporting
outcome.27 Median follow-up time of survivors differed
between the two cohorts included, reflecting a relatively
large proportion of patients from Norway included in the last
year quartile. However, it would be expected that longer
follow-up and an increasing number of events would only
strengthen the associations observed in the present study.
Pathological staging differed slightly between cohorts, with
different TNM editions used during different time periods in
the Norwegian cohort. However, previous work has sug-
gested that such a change would account for upstaging to
node positive disease in less than 3% of patients, with little
implication for prognosis.28,29
In conclusion, the present study represents the largest
prospective dataset analysing the systemic inflammatory
response as measured by mGPS in operable stage I–III
CRC to date. Results further confirm the clinical relevance
of assessment of the systemic inflammatory response as a
prognostic and potentially predictive marker in patients
with stage I–III colorectal cancer. The mGPS may be
readily applied to the staging of patients undergoing
potentially curative resection and should be considered a
mandatory characteristic for reporting not only in routine
clinical practice but also in future clinical trials.
AUTHOR CONTRIBUTIONS JHP, CK, PGH and DCM designed
the study. JHP, AJF, AHK and AO collected data. JHP, JG, CSDR,
CK and DCM analysed and interpreted the data. JHP, AJF, CK and
DCM wrote the first draft of the manuscript. All authors revised and
authorised the final submitted draft of the manuscript.
FUNDING There are no funding sources to declare.
DATA AVAILABILITY Anonymised data for this study can be
provided on request from the corresponding author.
DISCLOSURE The authors declare no conflicts of interest.
ETHICS APPROVAL AND CONSENT TO
PARTICIPATE Local Institutional approval was granted for use of
data from both Glasgow Royal Infirmary (West of Scotland Research
Ethics Committee) and Cancer Treatment Center, Sorlandet Hospital.
The study was performed in accordance with the Declaration of
Helsinki.
OPEN ACCESS This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons licence, and indicate
if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons licence, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons licence and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this licence, visit http://creativecommons.
org/licenses/by/4.0/.
REFERENCES
1. McAllister SS, Weinberg RA. The tumour-induced systemic
environment as a critical regulator of cancer progression and
metastasis. Nat Cell Biol. 2014;16(8):717–27. https://doi.org/10.
1038/ncb3015
J. H. Park et al.
2. Sjoquist KM, Renfro LA, Simes RJ, et al. Personalizing survival
predictions in advanced colorectal cancer: the ARCAD nomo-
gram project. J Natl Cancer Inst. 2018;110(6):638–48. https://d
oi.org/10.1093/jnci/djx253
3. ter Veer E, van Rijssen LB, Besselink MG, et al. Consensus
statement on mandatory measurements in pancreatic cancer trials
(COMM-PACT) for systemic treatment of unresectable disease.
Lancet Oncol. 2018;19(3):e151–60. https://doi.org/10.1016/s147
0-2045(18)30098-6
4. Dolan RD, Lim J, McSorley ST, Horgan PG, McMillan DC. The
role of the systemic inflammatory response in predicting out-
comes in patients with operable cancer: systematic review and
meta-analysis. Sci Rep. 2017;7(1):16717. https://doi.org/10.1038/
s41598-017-16955-5
5. Liu Y, He X, Pan J, Chen S, Wang L. Prognostic role of Glasgow
prognostic score in patients with colorectal cancer: evidence from
population studies. Sci Rep. 2017;7(1):6144. https://doi.org/10.
1038/s41598-017-06577-2
6. Park JH, Watt DG, Roxburgh CSD, Horgan PG, McMillan DC.
Colorectal cancer, systemic inflammation, and outcome: staging
the tumor and staging the host. Ann Surg. 2016;263(2):326–36. h
ttps://doi.org/10.1097/sla.0000000000001122
7. Carruthers R, Tho LM, Brown J, Kakumanu S, Mccartney E,
Mcdonald AC. Systemic inflammatory response is a predictor of
outcome in patients undergoing preoperative chemoradiation for
locally advanced rectal cancer. Color Dis. 2012;14(10):e701–7. h
ttps://doi.org/10.1111/j.1463-1318.2012.03147.x
8. Dolan RD, Laird BJA, Horgan PG, McMillan DC. The prognostic
value of the systemic inflammatory response in randomised
clinical trials in cancer: a systematic review. Crit Rev Oncol
Hematol. 2018;132:130–37. https://doi.org/10.1016/j.critrevonc.
2018.09.016
9. McMillan DC. The systemic inflammation-based Glasgow
Prognostic Score: a decade of experience in patients with cancer.
Cancer Treat Rev. 2013;39(5):534–40. https://doi.org/10.1080/1
5502724.2015.1134333
10. Williams G, Quirke P, Shepherd NAN, Hospital GR. Standards
and Datasets for Reporting Cancers. Dataset for Colorectal
Cancer (2 Nd Edition). 3rd ed. London: The Royal College of
Pathologists; 2007.
11. Park JH, Ishizuka M, McSorley ST, et al. Staging the tumor and
staging the host: a two centre, two country comparison of sys-
temic inflammatory responses of patients undergoing resection of
primary operable colorectal cancer. Am J Surg.
2018;216(3):458–64. https://doi.org/10.1016/j.amjsurg.2017.08.
044
12. Helgason A, Hickey E, Goodacre S, et al. mtDNA and the Islands
of the North Atlantic: estimating the proportions of Norse and
Gaelic ancestry. Am J Hum Genet. 2001;68(3):723–37. https://d
oi.org/10.1086/318785
13. Makanju A, LaRoche P, Zincir-Heywood AN. A comparison
between signature and GP-based IDSs for link layer attacks on
WiFi networks. Proc 2007 IEEE Symp Comput Intell Secur Def
Appl CISDA 2007. 2007;13(11):213–19. https://doi.org/10.1109/c
isda.2007.368156
14. Roxburgh CSD, Platt JJ, Leitch EF, Kinsella J, Horgan PG,
McMillan DC. Relationship between preoperative comorbidity,
systemic inflammatory response, and survival in patients under-
going curative resection for colorectal cancer. Ann Surg Oncol.
2011;18(4):997–1005. https://doi.org/10.1245/s10434-010-1410-
8
15. Kersten C, Louhimo J, A˚lgars A, et al. Increased C-reactive
protein implies a poorer stage-specific prognosis in colon cancer.
Acta Oncol (Madr). 2013;52(8):1691–8. https://doi.org/10.3109/
0284186x.2013.835494
16. Park JH, Van Wyk H, Roxburgh CSD, Horgan PG, Edwards J,
McMillan DC. Tumour invasiveness, the local and systemic
environment and the basis of staging systems in colorectal cancer.
Br J Cancer. 2017;116(11):1444–50. https://doi.org/10.1038/bjc.
2017.108
17. Mansouri D, McMillan DC, Crearie C, Morrison DS, Crighton
EM, Horgan PG. Temporal trends in mode, site and stage of
presentation with the introduction of colorectal cancer screening:
a decade of experience from the West of Scotland. Br J Cancer.
2015. https://doi.org/10.1038/bjc.2015.230
18. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB.
Elevated C-reactive protein levels in overweight and obese
adults. J Am Med Assoc. 1999;282(22):2131–5. https://doi.org/10.
1001/jama.282.22.2131
19. Aronson D, Bartha P, Zinder O, et al. Obesity is the major
determinant of elevated C-reactive protein in subjects with the
metabolic syndrome. Int J Obes. 2004;28(5):674–9. https://doi.
org/10.1038/sj.ijo.0802609
20. Shivappa N, Godos J, He´bert JR, et al. Dietary inflammatory
index and colorectal cancer risk—a meta-analysis. Nutrients.
2017;9(9):1043 https://doi.org/10.3390/nu9091043
21. Cuvillon P, Nouvellon E, Marret E, et al. American Society of
Anesthesiologists’ physical status system: a multicentre franco-
phone study to analyse reasons for classification disagreement.
Eur J Anaesthesiol. 2011;28(10):742–7. https://doi.org/10.1097/e
ja.0b013e328348fc9d
22. Park JH, Powell AG, Roxburgh CSD, Horgan PG, McMillan DC,
Edwards J. Mismatch repair status in patients with primary
operable colorectal cancer: associations with the local and sys-
temic tumour environment. Br J Cancer. 2016;114(5):562–70. h
ttps://doi.org/10.1038/bjc.2016.17
23. He WZ, Hu WM, Kong PF, et al. Systemic neutrophil lympho-
cyte ratio and mismatch repair status in colorectal cancer patients:
correlation and prognostic value. J Cancer.
2018;9(17):3093–100. https://doi.org/10.7150/jca.26669
24. Oliphant R, Mansouri D, Nicholson GA, McMillan DC, Horgan
PG, Morrison DS. Emergency presentation of node-negative
colorectal cancer treated with curative surgery is associated with
poorer short and longer-term survival. Int J Colorectal Dis. 2014.
https://doi.org/10.1007/s00384-014-1847-5
25. Crozier JEM, Leitch EF, McKee RF, Anderson JH, Horgan PG,
McMillan DC. Relationship between emergency presentation,
systemic inflammatory response, and cancer-specific survival in
patients undergoing potentially curative surgery for colon cancer.
Am J Surg. 2009. https://doi.org/10.1016/j.amjsurg.2007.12.052
26. Costas-Chavarri A, Temin S, Shah MA. Treatment of patients
with early-stage colorectal cancer: ASCO resource-stratified
guideline summary. J Oncol Pract. 2019. https://doi.org/10.1200/
jop.19.00011
27. Steele RJC, Brewster DH. Should we use total mortality rather
than cancer specific mortality to judge cancer screening pro-
grammes? No. BMJ. 2011;343:d6397. https://doi.org/10.1136/b
mj.d6397
28. Nagtegaal ID, Tot T, Jayne DG, et al. Lymph nodes, tumor
deposits, and TNM: are we getting better? J Clin Oncol.
2011;29(18):2487–92. https://doi.org/10.1200/jco.2011.34.6429
29. Ueno H, Mochizuki H, Akagi Y, et al. Optimal colorectal cancer
staging criteria in TNM classification. J Clin Oncol.
2012;30(13):1519–26. https://doi.org/10.1200/jco.2011.39.4692
Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Systemic Inflammation and Colorectal Cancer
